Global Health Limited (MEDANTA) Fair Value & Analysis
Healthcare · IN · Market cap ₹379B (≈ $4.0B) · ISIN INE474Q01031
What is Global Health Limited really worth?
A solid business, but trading 248% above our fair value of ₹421.92.
As of Aug 21, 2026, the fair value of Global Health Limited is ₹421.92 per share against a price of ₹1,469, so the fair value sits 71% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
Fair value as of: Aug 21, 2026
From 14 valuation models · updated 16 days ago
Share price +4.2% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (₹532.08). The favourable scenario is already priced in.
- Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 21, 2026.
How to read this chart
46‑month range ₹413.45 – ₹1,513 · fair‑value band ₹311.75 – ₹532.08 · the ₹1,469 price screens above the ₹421.92 fair value. Dashed = 300-day average. As of Aug 21, 2026.
Analysis
Global Health Limited (MEDANTA) currently trades at ₹1,469, while our model-based Fair Value estimate is ₹421.92, implying the stock looks roughly 248.2% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of ₹585.49 per share, and 0 of the 14 models we run sit above the ₹1,469 price. Bear case: the Asset-Based group reads lowest at ₹98.77, and 14 of the 14 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Global Health Limited generated revenue of ₹46.8B at a net margin of 11.9%. Revenue grew 26.5% year over year. It earns a return on equity of 15.0%. Net debt stands at ₹5.0B. Fundamentals as of Aug 21, 2026
Our scenario range runs from ₹311.75 (bear case) to ₹532.08 (bull case); at ₹1,469, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 1% below its 52-week high and 54% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −71%, MEDANTA screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2026 figures, and about 5 months have passed since. In that time the company retained roughly ₹9.03 per share, which is 2.1 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 14 models by family
Widest divergence: Growth Earnings (₹585.49) versus Asset-Based (₹98.77). Highest evidence: EPV (71).
Notify me when MEDANTA reaches fair value
Put MEDANTA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 70
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Global Health Limited engages in the provision of healthcare services in India. The company primarily offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, musculoskeletal disorders and orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, …
Full company description
Global Health Limited engages in the provision of healthcare services in India. The company primarily offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, musculoskeletal disorders and orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, plastic, aesthetic and reconstructive surgery, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, ayurveda, and dietetics and nutrition. It also offers lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, blood bank and e-ICU services, and health plans, as well as operates pharmacies. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in New Delhi, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Global Health Limited reported revenue of ₹44.1B in FY2026 versus ₹21.7B in FY2022, a compound +19.4%/yr. Reported net income was ₹5.6B in FY2026, compounding +29.8%/yr from FY2022.
MEDANTA screens 248% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 257 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $417.82 | $547.67 | +31% |
| Fresenius SE FRE | €45.25 | €32.15 | −29% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 241.00 SAR | 112.37 SAR | −53% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | −46% |
| Tenet Healthcare Corporation THC | $266.80 | $330.25 | +24% |
| DaVita Inc DVA | $180.68 | $186.49 | +3% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,818 | ₹2,955 | −66% |
| Fresenius Medical Care AG FME | €39.92 | €71.28 | +79% |
| Aier Eye Hospital Group 300015 | ¥8.25 | ¥7.67 | −7% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,005 | ₹284.87 | −72% |
Compare Global Health Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Global Health Limited (MEDANTA) overvalued or undervalued?
What is the fair value of MEDANTA?
What is the quality score of MEDANTA?
What is the price target for Global Health Limited (MEDANTA)?
What is the Global Health Limited stock forecast for 2026?
What is the revenue of Global Health Limited (MEDANTA)?
What is the net profit margin of MEDANTA?
Does Global Health Limited pay a dividend?
Watch Global Health Limited in the live analysis
One click puts Global Health Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.